Inhibition of endothelial cell chemotaxis toward FGF-2 by gefitinib associates with downregulation of Fes activity

International Journal of Oncology

Volumn 35, Issue 6, 2009, Pages 1305-1312

  Kanda, Shigeru ^a,b   Naba, Alexandra ^c   Miyata, Yasuyoshi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c INSTITUT CURIE   (France)

Author keywords

Chemotaxis; Endothelial cells; Fes; FGF 2; Gefitinib

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GEFITINIB; PROTEIN KINASE FES; VASCULOTROPIN A; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CHEMOTAXIS; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LAMELLIPODIUM; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; CHEMISTRY; DOWN REGULATION; DRUG EFFECT; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PROTEIN TERTIARY STRUCTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CHEMOTAXIS; DOWN-REGULATION; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-FES; QUINAZOLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 73949154075     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000448     Document Type: Article

References (45)

1. Folkman J: Angiogenesis-dependent diseases. Semin Oncol 28: 536-542, 2001.
2. Carmeliet P: Angiogenesis in health and disease. Nat Med 9: 653-660, 2003.
3. Shojaei F, Zhong C, Wu X, Yu L and Ferrara N: Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 18: 372-378, 2008.
4. Ellis LM and Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591, 2008.
5. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611, 2004.
6. Shibuya M: Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 41: 278-286, 2008.
7. Bergers G and Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603, 2008.
8. Ellis LM and Hicklin DJ: Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 14: 6371-6375, 2008.
9. Casanovas O, Hicklin DJ, Bergers G and Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309, 2005.
10. Wang Y and Becker D: Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 3: 887-893, 1997.
11. Czubayko F, Liaudet-Coopman ED, Aigner A, Tuveson AT, Berchem GJ and Wellstein A: A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 3: 1137-1140, 1997.
12. Compagni A, Wilgenbus P, Impagnatiello MA, Cotton M and Christofori G: Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 60: 7163-7169, 2000.
13. Rousseau B, Larrieu-Lahargue F, Javaerzat S, Guihem-Ducleon F, Beermann F and Bikfalvi A: The tyrp1-Tag/tyrp1-FGFR1-DN bigenic mouse: a model for selective inhibition of tumor development, angiogenesis, and invasion into the neural tissue by blockade of fibroblast growth factor receptor activity. Cancer Res 64: 2490-2495, 2004.
14. Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, Funa K, Brakenhielm E and Cao Y: Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neo-vascularization and metastasis. J Clin Invest 117: 2766-2777, 2007.
15. Willett CG, Boucher Y, Duda DG, Di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M and Lauwers GY: Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23: 8136-8139, 2005.
16. Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, Hawkins N, Rosenfeld R, Davy E, Graham K, Jacobsen F, Stevenson S, Ho J, Chen Q, Hartmann T, Michaels M, Kelley M, Li L, Sitney K, Martin F, Sun JR, Zhang N, Lu J, Estrada J, Kumar R, Coxon A, Kaufman S, Pretorius J, Scully S, Cattley R, Payton M, Coats S, Nguyen L, Desilva B, Ndifor A, Hayward I, Radinsky R, Boone T and Kendall R: Suppresion of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6: 507-516, 2004.
17. Batchelor TT, Sorensen AG, Di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY and Jain RK: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11: 83-95, 2007.
18. Smithgall TE, Rogers JA, Peters KL, Li J, Briggs SD, Lionberger JM, Cheng H, Shibata A, Scholtz B, Schreiner S and Dunham N: The c-Fes family of protein-tyrosine kinases. Crit Rev Oncog 9: 43-62, 1998.
19. Greer P: Closing in on the biological functions of Fps/Fes and Fer. Nat Rev Mol Cell Biol 3: 278-289, 2002.
20. Kanda S, Miyata Y, Kanetake H and Smithgall TE: Non-receptor protein-tyrosine kinases as molecular targets for anti-angiogenic therapy. Int J Mol Med 20: 113-121, 2007.
21. Rogers JA, Read RD, Li J, Peters KL and Smithgall TE: Autophosphorylation of the Fes tyrosine kinase. Evidence for an intermolecular mechanism involving two kinase domain tyrosine residues. J Biol Chem 271: 17519-17525, 1996.
22. Read RD, Lionberger JM and Smithgall TE: Oligomerization of the Fes tyrosine kinase. Evidence for a coiled-coil domain in the unique N-terminal region. J Biol Chem 272: 18498-18503, 1997.
23. Cheng HY, Schiavone AP and Smithgall TE: A point mutation in the N-terminal coiled-coil domain releases c-Fes tyrosine kinase activity and survival signaling in myeloid leukemia cells. Mol Cell Biol 21: 6170-6180, 2001.
24. Kanda S, Lerner EC, Tsuda S, Shono T, Kanetake H and Smithgall TE: The non-receptor protein-tyrosine kinase c-Fes is involved in fibroblast growth factor-2-induced chemotaxis of murine brain capillary endothelial cells. J Biol Chem 275: 10105-10111, 2000.
25. Mochizuki Y, Nakamura T, Kanetake H and Kanda S: Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn. J Cell Sci 115: 175-183, 2002.
26. Kanda S, Mochizuki Y and Kanetake H: Stromal cell-derived factor-1alpha induces tube-like structure formation of endothelial cells through phosphoinositide 3-kinase. J Biol Chem 278: 257-262, 2003.
27. Kanda S, Mochizuki Y, Miyata Y and Kanetake H: The role of c-Fes in vascular endothelial growth factor-A-mediated signaling by endothelial cells. Biochem Biophys Res Commun 306: 1056-1063, 2003.
28. Berger W, Setinek U, Mohr T, Kindas-Mügge I, Vetterlein M, Dekan G, Eckersberger F, Caldas C and Micksche M: Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. Int J Cancer 83: 415-423, 1999.
29. Fischer H, Taylor N, Allerstorfer S, Grusch M, Sonvilla G, Holzmann K, Setinek U, Elbling L, Cantonati H, Grasl-Kraupp B, Gauglhofer C, Marian B, Micksche M and Berger W: Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther 7: 3408-3419, 2008.
30. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA and Heasley LE: Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small cell lung cancer cells. Mol Pharmacol 75: 196-207, 2009.
31. Nishio, H, Nakamura, S, Horai, T, Ikegami, H and Matsuda M: Clinical and histopathologic evaluation of the expression of Ha-ras and fes oncogene products in lung cancer. Cancer 69: 1130-1136, 1992.
32. Huang SM, Li J, Armstrong EA and Harari PM: Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62: 4300-4306, 2002.
33. Baselga J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7 (Suppl. 4): 2-8, 2002.
34. Naba A, Reverdy C, Louvard D and Arpin M: Spatial recruitment and activation of the Fes kinase by ezrin promotes HGF-induced cell scattering. EMBO J 27: 38-50, 2008.
35. Wennström S, Landgren E, Blume-Jansen P and Claesson-Welsh L: The platelet-derived growth factor-β-receptor kinase insert confers specific signaling properties to a chimeric fibroblast growth factor receptor. J Biol Chem 267: 13749-13756, 1992.
36. Nakamura T, Kanda S, Kohno T, Yamamoto K, Maeda K, Matsuyama T and Kanetake H: Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility through partly phosphoinositide 3-kinase. Oncogene 20: 7610-7623, 2001.
37. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ and Gibson KH: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62: 5749-5754, 2002.
38. Moasser MM, Basso A, Averbuch SD and Rosen N: The tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61: 7184-7188, 2001.
39. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Müller S, Klebl B, Cotten M, Kéri G, Wissing J and Daub H: Cellular targets of gefitinib. Cancer Res 62: 379-382, 2005.
40. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lélias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP and Lockhart DJ: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336, 2005.
41. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM and Zarrinkar PP: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132, 2008.
42. Hjermstad SJ, Peters KL, Briggs SD, Glazer RI and Smithgall TE: Regulation of the human c-fes protein tyrosine kinase (p93c-fes) by its src homology 2 domain and major autophosphorylation site (Tyr-713). Oncogene 8: 2283-2292, 1993.
43. Filippakopoulos P, Kofler M, Hantschel O, Gish GD, Grebien F, Salah E, Neudecker P, Kay LE, Turk BE, Superti-Furga G, Pawson T and Knapp S: Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell 134: 793-803, 2008.
44. Fruman DA, Meyers RE and Cantley LC: Phosphoinositide kinases. Annu Rev Biochem 67: 481-507, 1998.
45. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H and Rowinsky EK: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20: 2240-2250, 2002.